Natarajan Muthusamy Selected Research

Natarajan Muthusamy Research Topics

Disease

52	Neoplasms (Cancer) 10/2023 - 12/2002
36	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2022 - 10/2007
17	Leukemia 10/2023 - 08/2006
9	Lymphoma (Lymphomas) 09/2023 - 10/2007
9	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2023 - 06/2009
8	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2023 - 06/2010
6	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 09/2007
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2023 - 04/2008
4	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 01/2008
4	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2016
3	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 01/2013
3	Bronchiolitis Obliterans Syndrome 01/2016 - 11/2014
2	Melanoma (Melanoma, Malignant) 01/2020 - 01/2016
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 09/2017
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 10/2012 - 04/2008
2	Multiple Sclerosis 12/2011 - 09/2007
2	Hepatocellular Carcinoma (Hepatoma) 06/2011 - 02/2008
1	Cytokine Release Syndrome 10/2023
1	Colitis 01/2019
1	Rectal Prolapse 01/2019
1	Disease Progression 01/2019
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018
1	Glioblastoma (Glioblastoma Multiforme) 01/2018
1	T-Cell Leukemia (Leukemia, T Cell) 01/2018
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2018

Drug/Important Bio-Agent (IBA)

12	Proteins (Proteins, Gene)FDA Link 06/2023 - 10/2002
9	ibrutinibIBA 09/2023 - 10/2013
9	Fingolimod Hydrochloride (FTY720)FDA Link 09/2015 - 09/2007
7	Monoclonal AntibodiesIBA 09/2023 - 03/2009
6	AntibodiesIBA 10/2022 - 10/2007
6	Lenalidomide (CC 5013)FDA Link 01/2016 - 10/2008
6	Rituximab (Mabthera)FDA Link 03/2013 - 05/2008
5	CytokinesIBA 10/2023 - 02/2011
5	milatuzumabIBA 09/2023 - 04/2011
5	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 10/2013
5	OSU-2SIBA 01/2022 - 06/2011
5	interleukin-21 (interleukin 21)IBA 01/2020 - 05/2008
4	RNA (Ribonucleic Acid)IBA 10/2020 - 06/2009
4	OligonucleotidesIBA 01/2013 - 06/2009
3	AntigensIBA 10/2023 - 02/2010
3	mouse MIRN29 microRNAIBA 01/2019 - 06/2009
3	MicroRNAs (MicroRNA)IBA 06/2012 - 06/2009
3	fludarabineIBA 05/2008 - 08/2006
2	Bispecific AntibodiesIBA 10/2023 - 04/2012
2	Chimeric Antigen ReceptorsIBA 09/2023 - 03/2016
2	Phosphotransferases (Kinase)IBA 02/2018 - 09/2007
2	Interleukin-10 (Interleukin 10)IBA 01/2018 - 12/2015
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2016 - 01/2016
2	emt protein-tyrosine kinase (IL2-inducible T-cell kinase)IBA 01/2016 - 11/2014
2	Interleukin-21 ReceptorsIBA 01/2016 - 06/2015
2	OligodeoxyribonucleotidesIBA 06/2015 - 02/2010
2	Cytarabine (Cytosar-U)FDA LinkGeneric 06/2015 - 02/2010
2	Antisense OligonucleotidesIBA 06/2015 - 01/2009
2	TetraspaninsIBA 01/2015 - 09/2013
2	Interleukin-2 (IL2)IBA 11/2014 - 01/2010
2	Transferrin (beta 2 Transferrin)IBA 05/2013 - 02/2010
2	Liposomes (Liposome)IBA 01/2013 - 04/2008
2	Immunoglobulin G (IgG)IBA 04/2012 - 03/2009
2	Cyclin D1IBA 12/2011 - 06/2010
2	Immunosuppressive Agents (Immunosuppressants)IBA 06/2011 - 02/2008
2	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2011 - 07/2010
2	Therapeutic UsesIBA 02/2010 - 06/2009
2	Messenger RNA (mRNA)IBA 01/2010 - 01/2009
2	DNA (Deoxyribonucleic Acid)IBA 06/2009 - 12/2002
1	blinatumomabIBA 10/2023
1	erdafitinibIBA 10/2023
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 10/2023
1	Cyclin-Dependent Kinase 9IBA 06/2023
1	Proteolysis Targeting ChimeraIBA 06/2023
1	CTLA-4 AntigenIBA 01/2022
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2022
1	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 01/2022
1	Receptor Tyrosine Kinase-like Orphan ReceptorsIBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	venetoclaxIBA 01/2021
1	EnzymesIBA 01/2020
1	BI-1347IBA 01/2020
1	idelalisibIBA 01/2019
1	BI 836858IBA 02/2018
1	BI 6727IBA 02/2018
1	Diphtheria ToxinIBA 01/2018
1	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 01/2018
1	tagraxofuspIBA 01/2018
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 01/2018
1	Fc Receptors (Fc Receptor)IBA 01/2018
1	Interleukin-3 (Interleukin 3)IBA 01/2018
1	Mitogen-Activated Protein KinasesIBA 11/2017
1	withaferin AIBA 09/2017
1	acalabrutinibIBA 08/2017
1	NK Cell Lectin-Like Receptor Subfamily CIBA 01/2016
1	monalizumabIBA 01/2016
1	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 06/2015
1	GTI2040IBA 06/2015
1	Lipid NanoparticlesIBA 06/2015

Therapy/Procedure

32	Therapeutics 11/2022 - 10/2007
7	Immunotherapy 10/2023 - 04/2010
4	Drug Therapy (Chemotherapy) 01/2021 - 02/2010
1	Euthanasia (Mercy Killing) 01/2019
1	Cell Transplantation 01/2018
1	Hematopoietic Stem Cell Transplantation 11/2014